The impact of metabotropic glutamate receptors into active neurodegenerative processes: A “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders

[1]  C. Ibáñez,et al.  Biology of GDNF and its receptors — Relevance for disorders of the central nervous system , 2017, Neurobiology of Disease.

[2]  K. C. Oliveira,et al.  Neuropathological relationship between major depression and dementia: A hypothetical model and review , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  Ofer Pasternak,et al.  In vivo imaging of neuroinflammation in schizophrenia , 2016, Schizophrenia Research.

[4]  Hongbing Wang,et al.  Acute inhibition of mGluR5 disrupts behavioral flexibility , 2016, Neurobiology of Learning and Memory.

[5]  N. Belluardo,et al.  Current disease modifying approaches to treat Parkinson’s disease , 2016, Cellular and Molecular Life Sciences.

[6]  Anthony E. Lang,et al.  Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD , 2016, Nature Reviews Neurology.

[7]  J. Bartolomé-Nebreda,et al.  Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. , 2016, Bioorganic & medicinal chemistry letters.

[8]  L. Baki,et al.  Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia , 2016, Science Signaling.

[9]  D. McKinzie,et al.  Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia , 2015, Biological Psychiatry.

[10]  B. McEwen,et al.  Stress dynamically regulates behavior and glutamatergic gene expression in hippocampus by opening a window of epigenetic plasticity , 2015, Proceedings of the National Academy of Sciences.

[11]  Fabio Sambataro,et al.  Baseline brain perfusion and brain structure in patients with major depression: a multimodal magnetic resonance imaging study. , 2015, Journal of psychiatry & neuroscience : JPN.

[12]  F. Nicoletti,et al.  Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage , 2015, Molecular Brain.

[13]  H. Morishita,et al.  Interneuron epigenomes during the critical period of cortical plasticity: Implications for schizophrenia , 2015, Neurobiology of Learning and Memory.

[14]  I. Bezprozvanny,et al.  Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease , 2015, The Journal of Neuroscience.

[15]  Carla Nasca,et al.  Mechanisms of stress in the brain , 2015, Nature Neuroscience.

[16]  S. Heckers,et al.  GABAergic mechanisms of hippocampal hyperactivity in schizophrenia , 2015, Schizophrenia Research.

[17]  F. Benes.  The GABA System in Schizophrenia: Cells, Molecules and Microcircuitry , 2015, Schizophrenia Research.

[18]  S. Sorbi,et al.  Monomeric ß-amyloid interacts with type-1 insulin-like growth factor receptors to provide energy supply to neurons , 2015, Front. Cell. Neurosci..

[19]  C. Lindsley,et al.  Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist , 2015, Neuropharmacology.

[20]  N. Simola,et al.  Dual target strategy: combining distinct non‐dopaminergic treatments reduces neuronal cell loss and synergistically modulates l‐DOPA‐induced rotational behavior in a rodent model of Parkinson's disease , 2015, Journal of neurochemistry.

[21]  D. Lewis,et al.  Alterations in Cortical Network Oscillations and Parvalbumin Neurons in Schizophrenia , 2015, Biological Psychiatry.

[22]  A. Palmeri,et al.  A key role for TGF-β1 in hippocampal synaptic plasticity and memory , 2015, Scientific Reports.

[23]  Anil Kumar,et al.  Therapeutic potential of mGluR5 targeting in Alzheimer's disease , 2015, Front. Neurosci..

[24]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[25]  Kari A. Johnson,et al.  Biased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR Currents , 2015, Neuron.

[26]  D. Holtzman,et al.  Three dimensions of the amyloid hypothesis: time, space and 'wingmen' , 2015, Nature Neuroscience.

[27]  C. Sánchez,et al.  Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. , 2015, European journal of pharmacology.

[28]  C. Sánchez,et al.  Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory , 2015, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  Stephen R. Morairty,et al.  Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[30]  M. Buuse,et al.  A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review , 2015, Neuroscience & Biobehavioral Reviews.

[31]  T. Schulze,et al.  Kraepelin revisited: schizophrenia from degeneration to failed regeneration , 2015, Molecular Psychiatry.

[32]  Daniel J Fridberg,et al.  Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: A meta-analysis , 2015, Psychiatry Research.

[33]  C. Sánchez,et al.  Serotonergic Regulation of Prefrontal Cortical Circuitries Involved in Cognitive Processing: A Review of Individual 5-HT Receptor Mechanisms and Concerted Effects of 5-HT Receptors Exemplified by the Multimodal Antidepressant Vortioxetine. , 2015, ACS chemical neuroscience.

[34]  J. López-Barneo,et al.  GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease , 2015, Front. Neuroanat..

[35]  Yu-ping Peng,et al.  Protection of TGF-β1 against Neuroinflammation and Neurodegeneration in Aβ1–42-Induced Alzheimer’s Disease Model Rats , 2015, PloS one.

[36]  P. Conn,et al.  Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics. , 2015, Current opinion in pharmacology.

[37]  Giuseppe Battaglia,et al.  Metabotropic glutamate receptors as drug targets: what's new? , 2015, Current opinion in pharmacology.

[38]  Giuseppe Battaglia,et al.  Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis , 2015, Neurobiology of Disease.

[39]  Carl-Fredrik Westin,et al.  The extent of diffusion MRI markers of neuroinflammation and white matter deterioration in chronic schizophrenia , 2015, Schizophrenia Research.

[40]  Y. Lu,et al.  Rapid-acting antidepressant-like effects of acetyl-l-carnitine mediated by PI3K/AKT/BDNF/VGF signaling pathway in mice , 2015, Neuroscience.

[41]  M. Roca,et al.  Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: a 6 month follow-up study. , 2015, Journal of affective disorders.

[42]  S. Chaki,et al.  Neurophysiologic and Antipsychotic Profiles of TASP0433864, a Novel Positive Allosteric Modulator of Metabotropic Glutamate 2 Receptor , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[43]  B. Mulsant,et al.  The Role of Untreated Psychosis in Neurodegeneration: A Review of Hypothesized Mechanisms of Neurotoxicity in First-Episode Psychosis , 2014, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[44]  B. Mcewen,et al.  Mind the gap: glucocorticoids modulate hippocampal glutamate tone underlying individual differences in stress susceptibility , 2014, Molecular Psychiatry.

[45]  O. Rascol,et al.  Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias. , 2014, Parkinsonism & related disorders.

[46]  S. Strittmatter,et al.  Therapeutic Molecules and Endogenous Ligands Regulate the Interaction between Brain Cellular Prion Protein (PrPC) and Metabotropic Glutamate Receptor 5 (mGluR5)* , 2014, The Journal of Biological Chemistry.

[47]  M. Ehrlich,et al.  Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer Aβ oligomer mouse , 2014, Molecular Psychiatry.

[48]  Sarah L. Huszar,et al.  Mechanism based neurotoxicity of mGlu5 positive allosteric modulators – Development challenges for a promising novel antipsychotic target , 2014, Neuropharmacology.

[49]  P. Kochunov,et al.  Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage. , 2014, Schizophrenia bulletin.

[50]  P. Masand,et al.  A review of current evidence for acetyl-l-carnitine in the treatment of depression. , 2014, Journal of psychiatric research.

[51]  A. Linden,et al.  mGluR3 knockout mice show a working memory defect and an enhanced response to MK-801 in the T- and Y-maze cognitive tests , 2014, Behavioural Brain Research.

[52]  S. Cregan,et al.  Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease , 2014, Molecular Brain.

[53]  I. Ito,et al.  Comprehensive behavioral study of mGluR3 knockout mice: implication in schizophrenia related endophenotypes , 2014, Molecular Brain.

[54]  A. Fasano,et al.  Maladaptive Plasticity in Levodopa-Induced Dyskinesias and Tardive Dyskinesias: Old and New Insights on the Effects of Dopamine Receptor Pharmacology , 2014, Front. Neurol..

[55]  F. Saravia,et al.  Astroglial mGlu3 receptors promote alpha-secretase-mediated amyloid precursor protein cleavage , 2014, Neuropharmacology.

[56]  D. Engblom,et al.  Mechanisms of Dopamine D1 Receptor-Mediated ERK1/2 Activation in the Parkinsonian Striatum and Their Modulation by Metabotropic Glutamate Receptor Type 5 , 2014, The Journal of Neuroscience.

[57]  Kari A. Johnson,et al.  Selective Actions of Novel Allosteric Modulators Reveal Functional Heteromers of Metabotropic Glutamate Receptors in the CNS , 2014, The Journal of Neuroscience.

[58]  M. Cenci,et al.  Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action , 2013, Experimental Neurology.

[59]  A. R. Durrant,et al.  Autoimmune-induced glutamatergic receptor dysfunctions: Conceptual and psychiatric practice implications , 2013, European Neuropsychopharmacology.

[60]  Gabriel Gold,et al.  Alzheimer disease therapy—moving from amyloid-β to tau , 2013, Nature Reviews Neurology.

[61]  P. Bargiotas,et al.  Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments , 2013, Neuropsychiatric disease and treatment.

[62]  H. Fillit,et al.  Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease , 2013, Alzheimer's Research & Therapy.

[63]  F. S. Bersani,et al.  l-Acetylcarnitine in dysthymic disorder in elderly patients: A double-blind, multicenter, controlled randomized study vs. fluoxetine , 2013, European Neuropsychopharmacology.

[64]  D. Volk,et al.  Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia , 2013, Neuroscience.

[65]  A. Vortmeyer,et al.  Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein , 2013, Neuron.

[66]  K. Nakazawa,et al.  Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia , 2013, Front. Behav. Neurosci..

[67]  C. Bundgaard,et al.  Repeated potentiation of the metabotropic glutamate receptor 5 and the alpha 7 nicotinic acetylcholine receptor modulates behavioural and GABAergic deficits induced by early postnatal phencyclidine (PCP) treatment , 2013, Neuropharmacology.

[68]  G. Marek,et al.  The two faces of the pharmacological interaction of mGlu2 and 5-HT2A – Relevance of receptor heterocomplexes and interaction through functional brain pathways , 2013, Neuropharmacology.

[69]  F. Gasparini,et al.  Metabotropic Glutamate Receptors for Parkinson's Disease Therapy , 2013, Parkinson's disease.

[70]  J. Krystal,et al.  Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond , 2013, Biological Psychiatry.

[71]  C. Lindsley,et al.  Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders. , 2013, Drug Discovery Today : Technologies.

[72]  M. Grilli,et al.  Upregulation of mGlu2 Receptors via NF-κB p65 Acetylation Is Involved in the Proneurogenic and Antidepressant Effects of Acetyl-L-Carnitine , 2013, Neuropsychopharmacology.

[73]  K. Gregory,et al.  A Novel Metabotropic Glutamate Receptor 5 Positive Allosteric Modulator Acts at a Unique Site and Confers Stimulus Bias to mGlu5 Signaling , 2013, Molecular Pharmacology.

[74]  Santo Di Nuovo,et al.  Role of the Transforming-Growth-Factor-β1 Gene in Late-Onset Alzheimer’s Disease: Implications for the Treatment , 2013, Current genomics.

[75]  F. Dudek,et al.  Unique Signaling Profiles of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Determine Differences in In Vivo Activity , 2013, Biological Psychiatry.

[76]  P. Gubellini,et al.  Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia , 2013, Neuropharmacology.

[77]  Huafu Chen,et al.  Decreased left middle temporal gyrus volume in antipsychotic drug-naive, first-episode schizophrenia patients and their healthy unaffected siblings , 2013, Schizophrenia Research.

[78]  S. Chaki,et al.  mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants , 2013, Neuropharmacology.

[79]  F. Nicoletti,et al.  L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors , 2013, Proceedings of the National Academy of Sciences.

[80]  Yuelong Jin,et al.  Meta-analysis of the transforming growth factor-β1 polymorphisms and susceptibility to Alzheimer’s disease , 2013, Journal of Neural Transmission.

[81]  L. Hurley,et al.  Neuroinflammation, Neurodegeneration, and Depression , 2013, Neurotoxicity Research.

[82]  D. Umbricht,et al.  Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target , 2013, Neuropharmacology.

[83]  S. Russo,et al.  Prenatal Stress Induces Schizophrenia-Like Alterations of Serotonin 2A and Metabotropic Glutamate 2 Receptors in the Adult Offspring: Role of Maternal Immune System , 2013, The Journal of Neuroscience.

[84]  D. Vancampfort,et al.  An impaired health related muscular fitness contributes to a reduced walking capacity in patients with schizophrenia: a cross-sectional study , 2013, BMC Psychiatry.

[85]  Carl-Fredrik Westin,et al.  Excessive Extracellular Volume Reveals a Neurodegenerative Pattern in Schizophrenia Onset , 2012, The Journal of Neuroscience.

[86]  P. Conn,et al.  Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. , 2012, Discovery medicine.

[87]  Y. Zhu,et al.  Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine produces antidepressant effects in rats: Role of brain-derived neurotrophic factor , 2012, Neuroscience.

[88]  R. von Bernhardi,et al.  Transforming growth factor‐β stimulates β amyloid uptake by microglia through Smad3‐dependent mechanisms , 2012, Journal of neuroscience research.

[89]  P. Kammermeier.  Functional and Pharmacological Characteristics of Metabotropic Glutamate Receptors 2/4 Heterodimers , 2012, Molecular Pharmacology.

[90]  Jimmy Lee,et al.  A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia , 2012, Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology.

[91]  M. Betts,et al.  Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6‐hydroxydopamine rat model of Parkinson's disease , 2012, British journal of pharmacology.

[92]  J. Bockaert,et al.  Dynamic remodeling of scaffold interactions in dendritic spines controls synaptic excitability , 2012, The Journal of cell biology.

[93]  T. Lai,et al.  Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model , 2012, Pharmacology Biochemistry and Behavior.

[94]  D. Magnuson,et al.  Acetyl-l-carnitine treatment following spinal cord injury improves mitochondrial function correlated with remarkable tissue sparing and functional recovery , 2012, Neuroscience.

[95]  Vaughan J. Carr,et al.  Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia , 2012, Neuroscience & Biobehavioral Reviews.

[96]  P. Bosco,et al.  The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression , 2012, European Neuropsychopharmacology.

[97]  S. Singh,et al.  Acetyl‐L‐carnitine‐mediated neuroprotection during hypoxia is attributed to ERK1/2‐Nrf2‐regulated mitochondrial biosynthesis , 2012, Hippocampus.

[98]  D. McKinzie,et al.  Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia , 2012, Neuropharmacology.

[99]  A. Guidotti,et al.  Pharmacological Activation of Group-II Metabotropic Glutamate Receptors Corrects a Schizophrenia-Like Phenotype Induced by Prenatal Stress in Mice , 2012, Neuropsychopharmacology.

[100]  P. Conn,et al.  Metabotropic glutamate receptors as therapeutic targets for schizophrenia , 2012, Neuropharmacology.

[101]  D. Lewis,et al.  NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. , 2012, Schizophrenia bulletin.

[102]  Rui Zhang,et al.  Neuroprotective Effects of Pre-Treament with l-Carnitine and Acetyl-l-Carnitine on Ischemic Injury In Vivo and In Vitro , 2012, International journal of molecular sciences.

[103]  R. Lefkowitz,et al.  Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. , 2012, Annual review of pharmacology and toxicology.

[104]  P. Conn,et al.  Targeting glutamate synapses in schizophrenia. , 2011, Trends in molecular medicine.

[105]  Davide Provasi,et al.  Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs , 2011, Cell.

[106]  R. Balice-Gordon,et al.  Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome , 2011, Neurology.

[107]  N. Belluardo,et al.  mGluR2/3 agonist LY379268, by enhancing the production of GDNF, induces a time-related phosphorylation of RET receptor and intracellular signaling Erk1/2 in mouse striatum , 2011, Neuropharmacology.

[108]  D. Selkoe,et al.  Resolving controversies on the path to Alzheimer's therapeutics , 2011, Nature Medicine.

[109]  T. Wichmann,et al.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. , 2011, Brain : a journal of neurology.

[110]  A. Guidotti,et al.  Epigenetic GABAergic targets in schizophrenia and bipolar disorder , 2011, Neuropharmacology.

[111]  F. Nicoletti,et al.  Metabotropic glutamate receptors: From the workbench to the bedside , 2011, Neuropharmacology.

[112]  L. Grégoire,et al.  The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. , 2011, Parkinsonism & related disorders.

[113]  J. Deussing,et al.  Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices , 2011, Neuropharmacology.

[114]  R. Boles,et al.  Beyond the serotonin hypothesis: Mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[115]  B. Ray,et al.  Autism, Alzheimer disease, and fragile X , 2011, Neurology.

[116]  E. Nisenbaum,et al.  Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies β-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective , 2011, Molecular Pharmacology.

[117]  M. Olive,et al.  Positive Allosteric Modulators of Type 5 Metabotropic Glutamate Receptors (mGluR5) and Their Therapeutic Potential for the Treatment of CNS Disorders , 2011, Molecules.

[118]  Allison C. Nugent,et al.  Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder , 2011, NeuroImage.

[119]  L. Prézeau,et al.  The complexity of their activation mechanism opens new possibilities for the modulation of mGlu and GABAB class C G protein-coupled receptors , 2011, Neuropharmacology.

[120]  G. Fiskum,et al.  Neuroprotection by Acetyl-L-Carnitine after Traumatic Injury to the Immature Rat Brain , 2011, Developmental Neuroscience.

[121]  C. Tamminga,et al.  Schizophrenia: treatment targets beyond monoamine systems. , 2011, Annual review of pharmacology and toxicology.

[122]  Eric Trinquet,et al.  A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[123]  Del D. Miller,et al.  Association between type‐three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia , 2011, Human psychopharmacology.

[124]  A. Brownell,et al.  Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease , 2010, Neuroscience Letters.

[125]  R. Faull,et al.  Altered distribution of mGlu2 receptors in β-amyloid-affected brain regions of Alzheimer cases and aged PS2APP mice , 2010, Brain Research.

[126]  P Jeffrey Conn,et al.  Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and In Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity , 2010, Molecular Pharmacology.

[127]  E. Nestler,et al.  Linking molecules to mood: new insight into the biology of depression. , 2010, The American journal of psychiatry.

[128]  Qin Li,et al.  A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys , 2010, Neurobiology of Disease.

[129]  W. Surewicz,et al.  Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. , 2010, The Journal of biological chemistry.

[130]  W. Klein,et al.  Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 , 2010, Neuron.

[131]  L. Grégoire,et al.  Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys , 2010, Neuropharmacology.

[132]  J. Brotchie,et al.  Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease , 2010, Journal of Pharmacology and Experimental Therapeutics.

[133]  M. Heilig,et al.  Alcohol-Induced Neurodegeneration, Suppression of Transforming Growth Factor-β, and Cognitive Impairment in Rats: Prevention by Group II Metabotropic Glutamate Receptor Activation , 2010, Biological Psychiatry.

[134]  P. S. St George-Hyslop,et al.  Group II Metabotropic Glutamate Receptor Stimulation Triggers Production and Release of Alzheimer's Amyloid β42 from Isolated Intact Nerve Terminals , 2010, The Journal of Neuroscience.

[135]  Jen-Chuen Hsieh,et al.  Structural and cognitive deficits in remitting and non-remitting recurrent depression: A voxel-based morphometric study , 2010, NeuroImage.

[136]  N. Belluardo,et al.  Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain , 2010, Neuroscience.

[137]  W. Singer,et al.  Abnormal neural oscillations and synchrony in schizophrenia , 2010, Nature Reviews Neuroscience.

[138]  Osamu Abe,et al.  Voxel-based analyses of gray/white matter volume and diffusion tensor data in major depression , 2010, Psychiatry Research: Neuroimaging.

[139]  W. Deng,et al.  Changes of Brain Morphometry in First-Episode, Drug-Naïve, Non–Late-Life Adult Patients with Major Depression: An Optimized Voxel-Based Morphometry Study , 2010, Biological Psychiatry.

[140]  P. Conn,et al.  Metabotropic glutamate receptors: physiology, pharmacology, and disease. , 2010, Annual review of pharmacology and toxicology.

[141]  M. Cenci,et al.  Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. , 2009, Parkinsonism & related disorders.

[142]  W. Danysz,et al.  Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. , 2009, European journal of pharmacology.

[143]  S. Kapur,et al.  Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia , 2009, The Pharmacogenomics Journal.

[144]  N. Belluardo,et al.  Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons , 2009, PloS one.

[145]  E. Nestler,et al.  Psychobiology and molecular genetics of resilience , 2009, Nature Reviews Neuroscience.

[146]  G. Zamponi.  Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[147]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[148]  E. Fernandes,et al.  Acetyl-l-carnitine provides effective in vivo neuroprotection over 3,4-methylenedioximethamphetamine-induced mitochondrial neurotoxicity in the adolescent rat brain , 2009, Neuroscience.

[149]  F. Liu,et al.  ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities , 2008, Journal of Pharmacology and Experimental Therapeutics.

[150]  Eric J. Nestler,et al.  The molecular neurobiology of depression , 2008, Nature.

[151]  D. Prasad,et al.  Hypoxia‐induced deactivation of NGF‐mediated ERK1/2 signaling in hippocampal cells: Neuroprotection by acetyl‐L‐carnitine , 2008, Journal of neuroscience research.

[152]  T. Schachtman,et al.  MGlu5 antagonism impairs exploration and memory of spatial and non-spatial stimuli in rats , 2008, Behavioural Brain Research.

[153]  M. Furey,et al.  Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression , 2008, Brain Structure and Function.

[154]  Henrik Walter,et al.  Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: a voxel-based morphometry study. , 2008, Journal of affective disorders.

[155]  Graeme Milligan,et al.  Identification of a serotonin/glutamate receptor complex implicated in psychosis , 2008, Nature.

[156]  S. Chaki,et al.  Mood disorders: regulation by metabotropic glutamate receptors. , 2008, Biochemical pharmacology.

[157]  V. Kaushal,et al.  Mechanisms of Microglia-Mediated Neurotoxicity in a New Model of the Stroke Penumbra , 2008, The Journal of Neuroscience.

[158]  Paul J. Harrison,et al.  Expression of a GRM3 Splice Variant is Increased in the Dorsolateral Prefrontal Cortex of Individuals Carrying a Schizophrenia Risk SNP , 2008, Neuropsychopharmacology.

[159]  W. Maier,et al.  DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study , 2008, Psychiatric genetics.

[160]  J. Bishop,et al.  Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. , 2007, Psychiatric genetics.

[161]  O. Combarros,et al.  Serum levels and genetic variation of TGF‐β1 are not associated with Alzheimer’s disease , 2007, Acta neurologica Scandinavica.

[162]  Beng-Choon Ho,et al.  MRI brain volume abnormalities in young, nonpsychotic relatives of schizophrenia probands are associated with subsequent prodromal symptoms , 2007, Schizophrenia Research.

[163]  B. Moghaddam,et al.  NMDA Receptor Hypofunction Produces Opposite Effects on Prefrontal Cortex Interneurons and Pyramidal Neurons , 2007, The Journal of Neuroscience.

[164]  L. Crepaldi,et al.  Altered Dimerization of Metabotropic Glutamate Receptor 3 in Schizophrenia , 2007, Biological Psychiatry.

[165]  B. Moghaddam,et al.  Positive Allosteric Modulation of Metabotropic Glutamate 5 (mGlu5) Receptors Reverses N-Methyl-D-Aspartate Antagonist-Induced Alteration of Neuronal Firing in Prefrontal Cortex , 2007, Biological Psychiatry.

[166]  G. Annoni,et al.  +10 T/C polymorphisms in the gene of transforming growth factor-β1 are associated with neurodegeneration and its clinical evolution , 2007, Mechanisms of Ageing and Development.

[167]  Ravi S. Menon,et al.  Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia , 2007, British Journal of Psychiatry.

[168]  Timothy Edward John Behrens,et al.  Anatomically related grey and white matter abnormalities in adolescent-onset schizophrenia. , 2007, Brain : a journal of neurology.

[169]  F. Fornai,et al.  Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. , 2007, Current medicinal chemistry.

[170]  F. Nicoletti,et al.  The Use of Knock-Out Mice Unravels Distinct Roles for mGlu2 and mGlu3 Metabotropic Glutamate Receptors in Mechanisms of Neurodegeneration/Neuroprotection , 2007, The Journal of Neuroscience.

[171]  W. Danysz,et al.  Antagonism of metabotropic glutamate receptor type 5 attenuates l‐DOPA‐induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson’s disease , 2007, Journal of neurochemistry.

[172]  John G. Csernansky,et al.  Neurodegeneration in Schizophrenia: Evidence from In Vivo Neuroimaging Studies , 2007, TheScientificWorldJournal.

[173]  L. Mucke,et al.  Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. , 2006, The Journal of clinical investigation.

[174]  T. Golde,et al.  Dysfunction of TGF- signaling in Alzheimers disease , 2006 .

[175]  Sergio Montes,et al.  Possible Mechanisms of Neurodegeneration in Schizophrenia , 2006, Neurochemical Research.

[176]  A. Hofman,et al.  Polymorphisms in the interleukin 6 and transforming growth factor β1 gene and risk of dementia The Rotterdam Study , 2006, Neuroscience Letters.

[177]  F. Nicoletti,et al.  Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine , 2006, The Journal of Neuroscience.

[178]  P. Calabresi,et al.  Acetyl-l-carnitine protects striatal neurons against in vitro ischemia: The role of endogenous acetylcholine , 2006, Neuropharmacology.

[179]  E. Smeraldi,et al.  A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia , 2006, European Neuropsychopharmacology.

[180]  P. Bramanti,et al.  Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease , 2006, Neurobiology of Disease.

[181]  G. MacQueen,et al.  An update on regional brain volume differences associated with mood disorders , 2006, Current opinion in psychiatry.

[182]  M. Amalric,et al.  Dysfunction of the cortico‐basal ganglia‐cortical loop in a rat model of early parkinsonism is reversed by metabotropic glutamate receptor 5 antagonism , 2005, The European journal of neuroscience.

[183]  R. Perry,et al.  Association studies of transforming growth factor‐β1 and Alzheimer's disease , 2005 .

[184]  P. Jeffrey Conn,et al.  Metabotropic glutamate receptors in the basal ganglia motor circuit , 2005, Nature Reviews Neuroscience.

[185]  Vicki L. Ellingrod,et al.  Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment , 2005, Schizophrenia Research.

[186]  R. Rosenthal,et al.  Mechanisms of Ischemic Neuroprotection by Acetyl‐l‐carnitine , 2005, Annals of the New York Academy of Sciences.

[187]  Nora Turjanski,et al.  Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. , 2005, Brain : a journal of neurology.

[188]  M. Owen,et al.  No evidence for association between polymorphisms in GRM3 and schizophrenia , 2005, BMC psychiatry.

[189]  C. Lindsley,et al.  A Novel Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Has in Vivo Activity and Antipsychotic-Like Effects in Rat Behavioral Models , 2005, Journal of Pharmacology and Experimental Therapeutics.

[190]  Deanna L. Taylor,et al.  Stimulation of Microglial Metabotropic Glutamate Receptor mGlu2 Triggers Tumor Necrosis Factor α-Induced Neurotoxicity in Concert with Microglial-Derived Fas Ligand , 2005, The Journal of Neuroscience.

[191]  W. Spooren,et al.  The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison , 2005, Psychopharmacology.

[192]  M. Amalric,et al.  Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson’s disease , 2005, Psychopharmacology.

[193]  E. Nisenbaum,et al.  Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s) , 2005, Psychopharmacology.

[194]  G. He,et al.  A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population , 2005, Schizophrenia Research.

[195]  James C. Overholser,et al.  Cellular changes in the postmortem hippocampus in major depression , 2004, Biological Psychiatry.

[196]  R. Gibbs,et al.  Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[197]  S. Nakanishi,et al.  Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent , 2004, Neuropharmacology.

[198]  Michael Marriott,et al.  Lower hippocampal volume in patients suffering from depression: a meta-analysis. , 2004, The American journal of psychiatry.

[199]  M. Amalric,et al.  Simultaneous Blockade of Adenosine A2A and Metabotropic Glutamate mGlu5 Receptors Increase their Efficacy in Reversing Parkinsonian Deficits in Rats , 2004, Neuropsychopharmacology.

[200]  S. Nakanishi,et al.  MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity , 2004, Neuropharmacology.

[201]  Hyoung-Gon Lee,et al.  Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer’s disease , 2004, Acta Neuropathologica.

[202]  Giuseppe Battaglia,et al.  Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.

[203]  A. Dilella,et al.  Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[204]  M. Amalric,et al.  Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats , 2003, The Journal of Neuroscience.

[205]  P Jeffrey Conn,et al.  Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.

[206]  F. Nicoletti,et al.  Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice , 2003, Neuropharmacology.

[207]  D. Lorrain,et al.  Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge , 2003, Neuropsychopharmacology.

[208]  Y. Fukumaki,et al.  Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia , 2003, Psychiatric genetics.

[209]  J. Jankovic,et al.  Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD , 2003, Neurology.

[210]  P. Renshaw,et al.  Smaller frontal lobe white matter volumes in depressed adolescents , 2002, Biological Psychiatry.

[211]  M. O'Neill,et al.  Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease , 2002, Pharmacology Biochemistry and Behavior.

[212]  G. Christoffersen,et al.  Differential effects of mGluR1 and mGlur5 antagonism on spatial learning in rats , 2002, Pharmacology Biochemistry and Behavior.

[213]  M. Cuzner,et al.  Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up‐regulated in Alzheimer's disease , 2002, Journal of neurochemistry.

[214]  G. Nowak,et al.  Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats , 2002, Neuropharmacology.

[215]  M. Amalric,et al.  Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism , 2002, The Journal of Neuroscience.

[216]  D. Mann,et al.  Association study of three polymorphisms of TGF-β1 gene with Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[217]  F. Nicoletti,et al.  Selective Blockade of mGlu5 Metabotropic Glutamate Receptors Is Protective against Methamphetamine Neurotoxicity , 2002, The Journal of Neuroscience.

[218]  G Bernardi,et al.  Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons , 2001, Neuroscience.

[219]  F. Nicoletti,et al.  Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[220]  S. Traynelis,et al.  Metabotropic Glutamate Receptors 1 and 5 Differentially Regulate CA1 Pyramidal Cell Function , 2001, The Journal of Neuroscience.

[221]  F. Moroni,et al.  Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges , 2001, British journal of pharmacology.

[222]  Y. Smith,et al.  Activation of Metabotropic Glutamate Receptor 5 Has Direct Excitatory Effects and Potentiates NMDA Receptor Currents in Neurons of the Subthalamic Nucleus , 2000, The Journal of Neuroscience.

[223]  S. DeKosky,et al.  Analysis of genetic polymorphisms in the transforming growth factor-β1 gene and the risk of Alzheimer's disease , 2000, Human Genetics.

[224]  G. Aghajanian,et al.  Serotonin model of schizophrenia: emerging role of glutamate mechanisms , 2000, Brain Research Reviews.

[225]  F. Nicoletti,et al.  Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection , 1999, Neuropharmacology.

[226]  P. Worley,et al.  Coupling of mGluR/Homer and PSD-95 Complexes by the Shank Family of Postsynaptic Density Proteins , 1999, Neuron.

[227]  F. Nicoletti,et al.  Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-β , 1998, The Journal of Neuroscience.

[228]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[229]  F. Bordi,et al.  Potentiation of NMDA and AMPA responses by group I mGluR in spinal cord motoneurons , 1997, Neuropharmacology.

[230]  F. Nicoletti,et al.  The Neuroprotective Activity of Group-II Metabotropic Glutamate Receptors Requires New Protein Synthesis and Involves a Glial–Neuronal Signaling , 1997, The Journal of Neuroscience.

[231]  G. Collingridge,et al.  (RS)-2-Chloro-5-Hydroxyphenylglycine (CHPG) Activates mGlu5, but not mGlu1, Receptors Expressed in CHO Cells and Potentiates NMDA Responses in the Hippocampus , 1997, Neuropharmacology.

[232]  F. Nicoletti,et al.  Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? , 1996, Trends in Neurosciences.

[233]  D. Schoepp,et al.  (1S,3R)‐1‐Aminocyclopentane‐1,3‐Dicarboxylic Acid‐Induced Increases in Cyclic AMP Formation in the Neonatal Rat Hippocampus Are Mediated by a Synergistic Interaction Between Phosphoinositide‐ and Inhibitory Cyclic AMP‐Coupled mGluRs , 1996, Journal of neurochemistry.

[234]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[235]  P. Sarzi-Puttini,et al.  A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. , 2015, Clinical and experimental rheumatology.

[236]  P. Jeffrey Conn,et al.  Development of allosteric modulators of GPCRs for treatment of CNS disorders , 2014, Neurobiology of Disease.

[237]  M. Cenci,et al.  Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse. , 2014, Parkinsonism & related disorders.

[238]  J. Pandit,et al.  Allosteric modulators for the treatment of schizophrenia: targeting glutamatergic networks. , 2013, Current topics in medicinal chemistry.

[239]  F. Blandini,et al.  A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease , 2013, Journal of Neural Transmission.

[240]  P. Conn,et al.  Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling. , 2012, Discovery medicine.

[241]  Bita Moghaddam,et al.  From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment , 2012, Neuropsychopharmacology.

[242]  L. Monteggia,et al.  Brain-derived neurotrophic factor and neuropsychiatric disorders. , 2012, Pharmacological reviews.

[243]  M. Cenci.  L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. , 2007, Parkinsonism & related disorders.

[244]  H. Car,et al.  Effect of MPEP in Morris water maze in adult and old rats. , 2007, Pharmacological reports : PR.

[245]  T. Golde,et al.  Dysfunction of TGF-beta signaling in Alzheimer's disease. , 2006, The Journal of clinical investigation.

[246]  R. Go,et al.  Association studies of transforming growth factor-beta 1 and Alzheimer's disease. , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[247]  H. Holcomb,et al.  Phenotype of schizophrenia: a review and formulation , 2005, Molecular Psychiatry.

[248]  G. Aghajanian,et al.  Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. , 2000, The Journal of pharmacology and experimental therapeutics.